1. Home
  2. EHI vs MDWD Comparison

EHI vs MDWD Comparison

Compare EHI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global High Income Fund Inc

EHI

Western Asset Global High Income Fund Inc

SELL

Current Price

$5.35

Market Cap

163.9M

Sector

Finance

ML Signal

SELL

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$12.64

Market Cap

162.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHI
MDWD
Founded
N/A
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.9M
162.2M
IPO Year
2003
2013

Fundamental Metrics

Financial Performance
Metric
EHI
MDWD
Price
$5.35
$12.64
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $30.67
AVG Volume (30 Days)
★ 136.4K
62.4K
Earning Date
01-01-0001
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$39.60
Revenue Next Year
N/A
$34.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.27
$11.84
52 Week High
$6.55
$19.93

Technical Indicators

Market Signals
Indicator
EHI
MDWD
Relative Strength Index (RSI) 38.06 38.38
Support Level $5.35 N/A
Resistance Level $5.50 $14.06
Average True Range (ATR) 0.07 0.44
MACD 0.01 -0.12
Stochastic Oscillator 36.74 16.36

Price Performance

Historical Comparison
EHI
MDWD

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: